Left atrial appendage occlusion for atrial fibrillation and bleeding diathesis

Author:

Kailey Balrik Singh12ORCID,Koa‐Wing Michael1,Sutaria Nilesh1,Mott Tom3,Sohaib Afzal1,Qureshi Norman1,Shi Christine1,Padam Pritpal1ORCID,Howard James2,Kanagaratnam Prapa12ORCID

Affiliation:

1. Imperial College Healthcare NHS Trust London UK

2. Imperial College London London UK

3. Abbott Medical Solihull UK

Abstract

AbstractBackgroundPatients with atrial fibrillation (AF) and likelihood of bleeding can undergo left atrial appendage occlusion (LAAO) as an alternative method of stroke prophylaxis. Short‐term anti‐thrombotic drugs are used postprocedure to offset the risk of device‐related thrombus, evidence for this practice is limited.ObjectivesTo investigate optimal postimplant antithrombotic strategy in high bleeding‐risk patients.MethodsPatients with AF and high‐risk for both stroke and bleeding undergoing LAAO were advised their perioperative drug therapy by a multidisciplinary physician panel. Those deemed to be at higher risk of bleeding from anti‐thrombotic drugs were assigned to minimal treatment with no antithrombotics or Aspirin‐alone. The remaining patients received standard care (STG) with a 12 week course of dual‐antiplatelets or anticoagulation postimplant. We compared mortality, device‐related thrombus, ischemic stroke, and bleeding events during the 90 days postimplant and long‐term. Event‐free survival was assessed using Kaplan−Meier survival analysis, with logrank testing for statistical significance.ResultsSeventy‐five patients underwent LAAO of whom 63 patients (84%) had a prior serious bleeding event. The 42 patients on minimal treatment were older (74.3 ± 7.7 vs. 71.2 ± 7.2) with higher HASBLED score (3.6 ± 0.9 vs. 3.3 ± 1.2) than the 33 patients having standard care. There were no device‐related thrombi or strokes in either group at 90 days postprocedure; STG had more bleeding events (5/33 vs. 0/42, p = 0.01) with associated deaths (3/33 vs. 0/42, p = 0.05). During long‐term follow‐up (median 2.2 years), all patients transitioned onto no antithrombotic drugs (43 patients [61%]) or a single‐antiplatelet (29 patients [39%]). There was no evidence of early minimal treatment adversely affecting long‐term outcomes.ConclusionsShort‐term anti‐thrombotic drugs may not be needed after LAAO implant in patients with high bleeding risk and could be harmful. Larger, prospective studies would be warranted to test these findings.

Publisher

Wiley

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3